Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The program now serves 6 million patients, and Elevance sees it as something that sets it apart from the competition.

Barclays raised the firm’s price target on Elevance Health (ELV) to $522 from $512 and keeps an Overweight rating on the shares following the ...